Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.31 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17146132 | 0.94 | SLC2A1 (0.33) | IDH1SLC2A1SLC2A3SLC2A4MEN1 | |
| SCHEMBL10150902 | 0.91 | KDM4E (0.33) | IDH1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL13090573 | 0.90 | CNR2 (0.34) | IDH1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10124212 | 0.90 | SLC2A1 (0.33) | SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL13085374 | 0.87 | RXRA (0.36) | IDH1F2F10 | |
| SCHEMBL10083881 | 0.87 | SLC2A1 (0.35) | IDH1SLC2A1SLC2A3SLC2A4MEN1 | |
| SCHEMBL685551 | 0.87 | IDH1 (0.32) | IDH1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10150934 | 0.85 | POLB (0.34) | IDH1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10151093 | 0.85 | NPC1 (0.35) | IDH1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10150903 | 0.85 | POLB (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790202-B2 | Anthranilamide derivatives as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-10-17 | — | — | US | disclosed |
| US-20120010250-A1 | Anthranilamide derivatives as pesticides | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010250-A1 | Anthranilamide derivatives as pesticides | ANTXR2, NQO2, AADAC | IDH1 332/4885SLC2A1 4752/4885SLC2A3 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.